89BIO (ETNB) Stock Price, News & Analysis

Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $9.71 to $10.20
• 50-Day Range: $6.27 to $10.57
• 52-Week Range: $4.16 to $11.84
• Volume: 1.91 million shs
• Average Volume: 1.50 million shs
• Market Capitalization: $1.43 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.43
• Consensus Rating: Buy

89BIO Stock Analysis - MarketRank™

89BIO scored higher than 42% of companies evaluated by MarketBeat, and ranked 692nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

89BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

89BIO has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 89BIO are expected to grow in the coming year, from ($3.19) to ($2.51) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 89BIO is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 89BIO is -2.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

89BIO has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.84% of the float of 89BIO has been sold short.

Short Interest Ratio / Days to Cover

89BIO has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in 89BIO has recently increased by 0.43%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

89BIO does not currently pay a dividend.

Dividend Growth

89BIO does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.84% of the float of 89BIO has been sold short.

Short Interest Ratio / Days to Cover

89BIO has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in 89BIO has recently increased by 0.43%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.63

News Sentiment

89BIO has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for 89BIO this week, compared to 5 articles on an average week.

Search Interest

5 people have searched for ETNB on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

3 people have added 89BIO to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 89BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $91,208.00 in company stock.

Percentage Held by Insiders

Only 2.80% of the stock of 89BIO is held by insiders.

ETNB Stock Analysis - Frequently Asked Questions

How have ETNB shares performed this year?

89BIO's stock was trading at $7.82 at the beginning of the year. Since then, ETNB shares have increased by 25.6% and is now trading at $9.82.
View the best growth stocks for 2025 here.

How were 89BIO's earnings last quarter?

89BIO (NASDAQ:ETNB) released its quarterly earnings data on Thursday, May, 1st. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.01.

When did 89BIO IPO?

89BIO (ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

How do I buy shares of 89BIO?

Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 89BIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 89BIO investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ETNB
• CIK: 1785173
• Web: www.89bio.com
• Phone: 415-432-9270
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $26.43
• High Stock Price Target: $49.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +165.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$367.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.44%
• Return on Assets: -70.17%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 18.03
• Quick Ratio: 18.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.34 per share
• Price / Book: 2.99

Miscellaneous

• Outstanding Shares: 145,980,000
• Free Float: 141,896,000
• Market Cap: $1.46 billion
• Optionable: Optionable
• Beta: 1.30